OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The construction will expand Catalent’s clinical supply facility in Schorndorf, Germany.
Catalent announced on April 6, 2023 that it has begun construction of a $20 million expansion project at its clinical supply facility in Schorndorf, Germany. The project will increase the site’s footprint by 32,000 ft2 and add capacity for the storage and handling of clinical trial supply materials at controlled room temperatures between 15 °C and 25 °C.
Furthermore, Catalent will create space in the original building to accommodate the installation of a new, fully automatic bottle-filling line. The company will also establish a dedicated area for its FastChain supply service. Work on the site is expected to be completed by June 2024.
Catalent’s Schorndorf clinical supply facility opened in 1996 and provides comprehensive clinical supply services, including multi-lingual project services, comparator sourcing, primary and secondary packaging, labeling, clinical storage and distribution, and returns and destruction. The company’s FastChain supply service is a continuous good manufacturing practice approach that decouples primary from secondary packaging to enable timely and cost-effective adaptation and regional supply of clinical materials.
“Our site in Schorndorf plays a key strategic role in our global clinical supply network, and this expansion will provide much needed capacity and capabilities to meet the growing needs of customers,” said Ricky Hopson, president, division head for clinical development & supply at Catalent, in a company press release. “Additional temperature-controlled handling, storage, and distribution means the facility is well-equipped to respond to the growing demand for clinical supply capacity and services in the region, including for products requiring cold chain support. Working closely with our adjacent oral dose manufacturing center of excellence, and our European development centers for oral, biologic, cell therapy and gene therapy products, customers have access to fully integrated development, clinical packaging, and distribution solutions.”